CLINICAL TRIALS
CLINICAL TRIALS
Our clinical research and trial program was started in 1998 with the goal of providing our patients with the most cutting edge urological care.
- We have since conducted over 500 industry and federally funded studies.
- Clinical trials follow strict scientific standards. These standards help protect patients and produce more reliable study results.
- Our research center is a true center of excellence making new treatments and medications available to our patients in the Inland Empire that otherwise are available only at National Cancer Center Network hospitals.
- Our office has played a pivotal role in the development of multiple medications:
- Eligard (Hormone therapy for Prostate Cancer)
- Provenge (Immunotherapy for Prostate Cancer)
- Xtandi and Zytiga (Second line Antiandrogen for Prostate Cancer)
- Levaquin (antibiotic)
- Levitra (ED medication)
- Vesicare, Detrol, Ditropan XL,Toviaz, and Myrbetriq (Overactive Bladder medications)
CLINICAL TRIALS
Our clinical research and trial program was started in 1998 with the goal of providing our patients with the most cutting edge urological care.
We have since conducted over 500 industry and federally funded studies.
Clinical trials follow strict scientific standards. These standards help protect patients and produce more reliable study results.
Our research center is a true center of excellence making new treatments and medications available to our patients in the Inland Empire that otherwise are available only at National Cancer Center Network hospitals.
Our office has played a pivotal role in the development of multiple medications:
- Eligard (Hormone therapy for Prostate Cancer
- Provenge (Immunotherapy for Prostate Cancer)
- Xtandi and Zytiga (Second line Antiandrogen for Prostate Cancer)
- Levaquin (antibiotic)
- Levitra (ED medication)
- Vesicare, Detrol, Ditropan XL,Toviaz, and Myrbetriq (Overactive Bladder medications)
The following is a list of active research protocols at this moment:
Veracity
Randomized active-controlled phase 3 study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed treatment with one androgen receptor targeting agent. Currently enrolling patients.
Triton 3
Randomized open label phase 3 study evaluating the PARP Inhibitor, Rucaparib, vs. physician’s choice therapy for patients with metastatic castration-resistant prostate cancer. Closed
Tavanta
Phase 3 study investigating the efficacy and safety of TAVT-45 (Abiraterone Acetate) granules for oral suspension (a novel Abiraterone Acetate formulation) relative to a reference Abiraterone Acetate formulation in patients with metastatic castration sensitive and metastatic castration resistant prostate cancer. Currently enrolling patients.
An open label
Proof of concept and dose finding phase 1/2b study of VERU-100 in men with advanced prostate cancer. Currently enrolling patients
Amplitude
A study of Niraparib in combination with Abiraterone Acetate plus Prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-altered metastatic castration- sensitive prostate cancer, ongoing.
Magnitude
A study of Niraparib in combination with Abiraterone Acetate plus Prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-altered metastatic castration- resistant prostate cancer, closed.
